This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Unifiram
An AMPAkine nootropic structurally related to sunifiram but reportedly 1,000 times more potent than piracetam at enhancing long-term potentiation - acting as a positive allosteric modulator of AMPA receptors and activator of mGlu5 receptors with robust anti-amnesic effects in animal studies.
Benefits
What is Unifiram?
Unifiram (DM-232) is a synthetic AMPAkine nootropic compound developed at the University of Firenze in Italy, structurally related to its more well-known sibling sunifiram (DM-235). Both compounds were created by a team led by Bhunandass Ghelardini as part of a systematic effort to develop cognition-enhancing agents based on modifications to the piracetam molecular scaffold. Unifiram is estimated to be approximately 1,000 times more potent than piracetam in enhancing long-term potentiation (LTP) in hippocampal slice preparations, and some researchers consider it slightly more potent than sunifiram in certain assay systems.
A key study by Ghelardini et al. published in Il Farmaco (2002) demonstrated that unifiram reversed amnesia induced by scopolamine, baclofen, mecamylamine, and clonidine in mice at doses of 0.01-0.1 mg/kg - confirming anti-amnesic activity across cholinergic, GABAergic, nicotinic, and alpha-2 adrenergic disruption models. A 2003 follow-up study in Behavioural Brain Research showed that unifiram enhanced passive avoidance retention and demonstrated anxiolytic-like effects in the elevated plus maze at sub-milligram doses. The compound acts primarily as a positive allosteric modulator of AMPA receptors, enhancing the speed and magnitude of glutamatergic excitatory transmission. Additionally, unifiram activates mGlu5 (metabotropic glutamate receptor 5), which plays a critical role in synaptic plasticity and memory consolidation in the hippocampus. Despite this compelling preclinical data, no human clinical trials have ever been conducted, and unifiram remains an unregulated research chemical.
- AMPA receptor positive allosteric modulation: Enhances the response of AMPA receptors to glutamate, increasing the amplitude and duration of excitatory postsynaptic currents critical for rapid synaptic signalling and learning
- Long-term potentiation enhancement: Facilitates LTP in hippocampal CA1 neurons via CaMKII and protein kinase C activation, strengthening synaptic connections involved in memory formation
- mGlu5 receptor activation: Activates metabotropic glutamate receptor 5, which modulates NMDA receptor function and intracellular calcium signalling to promote synaptic plasticity and memory consolidation
- Acetylcholine release: Stimulates cortical and hippocampal acetylcholine release, supporting attentional processes and working memory through enhanced cholinergic tone
- Broad-spectrum anti-amnesic activity: Reverses memory impairment caused by disruption of cholinergic, GABAergic, nicotinic, and adrenergic systems, suggesting a mechanism of action that converges on fundamental memory consolidation pathways
- Community-reported dose: 2-5 mg per dose, taken sublingually for enhanced bioavailability. This is entirely based on anecdotal reports and extrapolation from animal research
- Sublingual administration: Most users prefer sublingual dosing for faster onset (15-30 minutes) and potentially improved absorption compared to oral ingestion
- Frequency: Typically used 1-3 times daily, often in an as-needed fashion before cognitively demanding tasks
- Starting dose: Begin with 1-2 mg to assess individual sensitivity before increasing. The high potency relative to classical racetams demands conservative initial dosing
- Cycling: Due to the complete lack of long-term safety data, most protocols recommend cycling (e.g. 5 days on, 2 days off or 3 weeks on, 1 week off)
- No human clinical trials: Unifiram has never been tested in controlled human studies. All efficacy and safety data derives from rodent experiments and anecdotal community reports
- Excitotoxicity risk: As an AMPAkine that enhances glutamatergic transmission, there is a theoretical risk of excitotoxicity at excessive doses, potentially causing neuronal damage through calcium overload
- Seizure threshold: Enhanced AMPA and glutamate receptor activity may lower seizure threshold. Individuals with epilepsy or a history of seizures should avoid unifiram entirely
- Unknown long-term effects: The consequences of chronic AMPA receptor potentiation and mGlu5 activation in humans are completely unknown. Receptor downregulation and tolerance are possible
- Research chemical status: Unifiram is not approved for human consumption in any country. Quality, purity, and accurate dosing from research chemical vendors cannot be guaranteed
Natural Sources & Forms
- Research chemical vendors: Available from select nootropic suppliers as powder, typically in small quantities suitable for milligram-scale dosing
- No pharmaceutical production: Unifiram has never been manufactured by a pharmaceutical company and exists solely as a research compound
- Powder form: Most commonly supplied as the free base or hydrochloride salt in powder form, requiring an accurate milligram scale for safe dosing
- Solution form: Some vendors offer pre-dissolved solutions for volumetric dosing, which may improve dosing accuracy at such small quantities
Frequently Asked Questions
An AMPAkine nootropic structurally related to sunifiram but reportedly 1,000 times more potent than piracetam at enhancing long-term potentiation - acting as a positive allosteric modulator of AMPA receptors and activator of mGlu5 receptors with robust anti-amnesic effects in animal studies.
The key benefits of Unifiram include: Cognitive Enhancement, Creativity, Energy, Focus, Memory, Motivation.
AMPA receptor positive allosteric modulation: Enhances the response of AMPA receptors to glutamate, increasing the amplitude and duration of excitatory postsynaptic currents critical for rapid synaptic signalling and learning Long-term potentiation enhancement: Facilitates LTP in hippocampal CA1 neurons via CaMKII and protein kinase C activation, strengthening synaptic connections involved in memory formation mGlu5 receptor activation: Activates metabotropic glutamate receptor 5, which modulates NMDA receptor function and intracellular calcium signalling to promote synaptic plasticity and memory consolidation Acetylcholine release: Stimulates cortical and hippocampal acetylcholine release, supporting attentional processes and working memory through enhanced cholinergic tone Broad-spectrum anti-amnesic activity: Reverses memory impairment caused by disruption of cholinergic, GABAergic, nicotinic, and adrenergic systems, suggesting a mechanism of action that converges on fundamental memory consolidation pathways
Community-reported dose: 2-5 mg per dose, taken sublingually for enhanced bioavailability. This is entirely based on anecdotal reports and extrapolation from animal research Sublingual administration: Most users prefer sublingual dosing for faster onset (15-30 minutes) and potentially improved absorption compared to oral ingestion Frequency: Typically used 1-3 times daily, often in an as-needed fashion before cognitively demanding tasks Starting dose: Begin with 1-2 mg to assess individual sensitivity before increasing. The high potency relative to classical racetams demands conservative initial dosing Cycling: Due to the complete lack of long-term safety data, most protocols recommend cycling (e.g. 5 days on, 2 days off or 3 weeks on, 1 week off)
No human clinical trials: Unifiram has never been tested in controlled human studies. All efficacy and safety data derives from rodent experiments and anecdotal community reports Excitotoxicity risk: As an AMPAkine that enhances glutamatergic transmission, there is a theoretical risk of excitotoxicity at excessive doses, potentially causing neuronal damage through calcium overload Seizure threshold: Enhanced AMPA and glutamate receptor activity may lower seizure threshold. Individuals with epilepsy or a history of seizures should avoid unifiram entirely Unknown long-term effects: The consequences of chronic AMPA receptor potentiation and mGlu5 activation in humans are completely unknown. Receptor downregulation and tolerance are possible Research chemical status: Unifiram is not approved for human consumption in any country. Quality, purity, and accurate dosing from research chemical vendors cannot be guaranteed
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!